WOBURN, Mass.–(BUSINESS WIRE)–We are pleased to announce that Aphios Pharma LLC will host a live webinar followed by Q&A on the science and technology of cannabis as a medicine.
This webinar will cover the science and technology of cannabis and cannabinoids as a medicine for several chronic diseases. On the science side, we will cover research and use of cannabis for anxiety and observational studies at the MIND Institute, Harvard Medical School. We will also touch on the research and use of cannabis for pain, opioid use disorder and multiple sclerosis. On the technology side, we will cover the manufacturing of pharmaceutical-grade cannabinoids from Cannabis sativa (marijuana) following current Good Manufacturing Practices (cGMP) of the US FDA. We will also cover the nanoencapsulation of these cannabinoids to improve their stability and sustain their release in the body to improve both safety and efficacy.
Join Aphios Pharma Founder and CEO, Dr. Trevor P. Castor, along with guests Dr. Staci A. Gruber, Associate Professor, Harvard Medical School, and Dr. Judith L. Palmer-Castor, Director, Clinical and Regulatory Affairs on June 23, 2022, from 1pm to 1:45pm EST for a discussion on the science of medical cannabis and the drug-delivery nanotechnologies that make cannabis more medically effective.
To learn more and register for the event, visit:
https://www.eventbrite.com/e/aphios-pharma-webinar-tickets-354629254647
About Aphios Pharma LLC:
Aphios Pharma is dedicated to the delivery, development and commercialization of cannabis-based drugs for CNS and other debilitating disorders. We are developing FDA-approved, cannabis-based drugs for treating highly unmet central and peripheral nervous system disorders such as opioid addiction and chemotherapy induced peripheral neuropathic pain that are only acutely addressed by medical marijuana. Aphios Pharma is utilizing patented and proprietary manufacturing technologies for producing pharmaceutical-grade cannabinoids, and patented and proprietary drug delivery nanotechnologies to improve the oral bioavailability of disease-specific cannabinoids and control their release for the treatment of chronic diseases. We are thus converting natural drugs that are anecdotally used to treat acute conditions into well-defined and characterized drugs for chronic conditions.
